Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 11/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 9/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | TNNI3 | P19429 | 1/20 | 0.34 |
| ▸ | TNNT2 | P45379 | 1/20 | 0.34 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.34 |
| ▸ | TNKS | O95271 | 2/20 | 0.34 |
| ▸ | PARP1 | P09874 | 2/20 | 0.34 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.34 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.34 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30738817 | 1.00 | CRBN (0.40) | CRBNDDB1ALDH1A1KMT2AFFAR4 | |
| SCHEMBL27178764 | 0.84 | FFAR4 (0.37) | CRBNDDB1ALDH1A1KMT2AFFAR4 | |
| SCHEMBL30738835 | 0.84 | FFAR4 (0.37) | CRBNDDB1ALDH1A1KMT2AFFAR4 | |
| SCHEMBL27178719 | 0.81 | CRBN (0.43) | CRBNDDB1TNKSTNKS2 | |
| SCHEMBL23066000 | 0.80 | CRBN (0.50) | CRBNDDB1ALDH1A1KMT2AMEN1 | |
| SCHEMBL27362849 | 0.79 | ALDH1A1 (0.43) | CRBNDDB1ALDH1A1KMT2AMEN1 | |
| SCHEMBL17542771 | 0.79 | ALDH1A1 (0.46) | ALDH1A1KMT2AFFAR4MAPTNR3C1 | |
| SCHEMBL2769245 | 0.79 | FFAR4 (0.49) | ALDH1A1KMT2AFFAR4MAPTNR3C1 | |
| SCHEMBL17893532 | 0.77 | ALDH1A1 (0.43) | ALDH1A1KMT2AFFAR4MAPTMEN1 | |
| SCHEMBL22857611 | 0.76 | ALDH1A1 (0.45) | CRBNDDB1ALDH1A1FFAR4TNKS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240101540-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | ABBVIE BIOTECHNOLOGY LTD (BM) | 2024-03-28 | — | — | US | disclosed |
| WO-2024026081-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | RIBON THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240101540-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | PARP14, PARP15, PARP16 | CRBN 422/4885DDB1 54/4885ALDH1A1 3504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.